ArticleBMC genomics2019
Proteomic and transcriptomic analyses of early and late-chronic Toxoplasma gondii infection shows novel and stage specific transcripts.
Article in BMC genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Article
- Development and validation of a gra1-bag1 RT-qPCR assay as an alternative to the mouse bioassay for assessing Toxoplasma gondii viability.Scientific reports · 2026Article
- Dense granule proteins: key mediators ofFrontiers in medicine · 2026Review
- Regulation of the developmental programs in Toxoplasma by a novel SNF2L-containing chromatin remodeling complex.Nature communications · 2025Article
- High-Throughput Repurposing Screen Reveals Compounds with Activity againstACS infectious diseases · 2025Article
- Modeling Toxoplasma gondii-gut early interactions using a human microphysiological system.PLoS neglected tropical diseases · 2025Article
- Article
- High Throughput Repurposing Screen Reveals Compounds with Activity AgainstbioRxiv : the preprint server for biology · 2024Article
- Constitutive upregulation of transcription factors underlies permissive bradyzoite differentiation in a natural isolate ofbioRxiv : the preprint server for biology · 2024Article
- Generation of MatureBio-protocol · 2024Article
- Proteomics Applications inPathogens (Basel, Switzerland) · 2023Review
- A state-of-the-art methodology for high-throughput in silico vaccine discovery against protozoan parasites and exemplified with discovered candidates for Toxoplasma gondii.Scientific reports · 2023Article
- Invasion ofProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Unravelling the sexual developmental biology ofFrontiers in cellular and infection microbiology · 2023Article
- Article
- The transcriptome from asexual to sexual in vitro development of Cystoisospora suis (Apicomplexa: Coccidia).Scientific reports · 2022Article
- Bicyclic azetidines target acute and chronic stages of Toxoplasma gondii by inhibiting parasite phenylalanyl t-RNA synthetase.Nature communications · 2022Article
- Article
- Paving the Way: Contributions of Big Data to Apicomplexan and Kinetoplastid Research.Frontiers in cellular and infection microbiology · 2022Review
- CircRNA and miRNA expression analysis in livers of mice withFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe protozoan pathogen Toxoplasma gondii has the unique ability to develop a chronic infection in the brain of its host by transitioning from the fast growing tachyzoite morphology to latent bradyzoite morphology. A hallmark of the bradyzoite is the development of neuronal cysts that are resilient against host immune response and current therapeutics. The bradyzoite parasites within the cyst have a carbohydrate and protein-rich wall and a slow-replication cycle, allowing them to remain hidden from the host. The intracellular, encysted lifestyle of T. gondii has made them recalcitrant to molecular analysis in vivo.
resultsHere, we detail the results from transcriptional and proteomic analyses of bradyzoite-enriched fractions isolated from mouse brains infected with T. gondii over a time course of 21 to 150 days. The enrichment procedure afforded consistent identification of over 2000 parasitic peptides from the mixed-organism sample, representing 366 T. gondii proteins at 28, 90, and 120 day timepoints. Deep sequencing of transcripts expressed during these three timepoints revealed that a subpopulation of genes that are transcriptionally expressed at a high level. Approximately one-third of these transcripts are more enriched during bradyzoite conditions compared to tachyzoites and approximately half are expressed at similar levels during each phase. The T. gondii transcript which increased the most over the course of chronic infection, sporoAMA1, shows stage specific isoform expression of the gene.
conclusionsWe have expanded the transcriptional profile of in vivo bradyzoites to 120 days post-infection and provided the first in vivo proteomic profile of T. gondii bradyzoites. The RNA sequencing depth of in vivo bradyzoite T. gondii was over 250-fold greater than previous reports and allowed us to identify low level transcripts and a novel bradyzoite-specific isoform of sporoAMA1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.